German CDMO Richter-Helm Triples cGMP Production Capacity to Accommodate Global Market Demand

May 6, 2023 – Biotechnology


HAMBURG, Germany, May 06, 2021 —Richter-Helm BioLogics GmbH & Co. KG,
a leading Germany-based, cGMP compliant biopharmaceutical Contract
Development and Manufacturing Organization (CDMO) announced today the
start of construction for an expansion project at its cGMP manufacturing
facility in Bovenau, Germany. The new multi-product biological
manufacturing facility is expected to begin full-scale operations and
manufacturing by the end of 2023.

“The market for pharmaceutical biotechnology has been continuously
growing and further growth is expected. In order to accommodate demand
for high value biopharmaceutical products, Richter-Helm recently started
expansion of its microbial manufacturing capacity and continues to push
its overall growth strategy.” said Dr. Kai Pohlmeyer, Managing Director at Richter-Helm.  The
basic engineering of the new facility has been completed and the
ground-breaking ceremony took place on May 5th, 2021 by the management
team of Richter-Helm, who initiated construction of the new facility.

Richter-Helm
and its mother companies Gedeon Richter and HELM AG will invest close
to 70 million Ä to triple the current production capacity and expand its
existing warehouse, laboratory, and administration buildings.

Currently, Richter-Helm operates two cGMP-compliant production
facilities located in Hannover and Bovenau, Germany, with bioreactor
capacities of up to 1,500 litres. The Bovenau expansion covers
installment of two additional highly flexible and fully equipped
production trains with interchangeable product flows. Bioreactor
capacities of 300 litres and 1,500 litres will be added. The production
site will reach a total area of about 10,000 m≤ and includes all
necessary utilities and infrastructure, like QC-labs, warehouse and
technical areas.

Dr. Kai Pohlmeyer further explains: “With the
addition of two new manufacturing trains, Richter-Helm is supporting the
demand of its existing customers and the needs of the growing
biopharmaceutical market. We will be more flexible and more efficient in
bringing products of our worldwide pharmaceutical clients to market. We
also expect to create a significant number of new jobs for qualified
professionals once the plant becomes fully operational”.